Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
15.30
+0.23 (1.53%)
At close: Jun 26, 2026, 4:00 PM EDT
15.20
-0.10 (-0.65%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Immunic Employees
Immunic had 95 employees as of March 31, 2026. The number of employees increased by 3 or 3.26% since the number was last reported on December 31, 2025.
Employees
95
Change
3
Growth
3.26%
Revenue / Employee
n/a
Profits / Employee
-$1,097,758
Market Cap
208.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 95 | 3 | 3.26% |
| Dec 31, 2025 | 92 | 1 | 1.10% |
| Dec 31, 2024 | 91 | 14 | 18.18% |
| Dec 31, 2023 | 77 | 11 | 16.67% |
| Dec 31, 2022 | 66 | 11 | 20.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Karyopharm Therapeutics | 228 |
| Codexis | 146 |
| Nkarta | 108 |
| Alector | 103 |
| Keros Therapeutics | 87 |
| Camp4 Therapeutics | 48 |
| Q32 Bio | 22 |
IMUX News
- 17 days ago - Immunic to Participate in Investor, Industry and Scientific Conferences in June - PRNewsWire
- 26 days ago - Immunic Slides: Corporate presentation - Filings
- 4 weeks ago - Immunic Proxy statement: Proxy filing - Filings
- 4 weeks ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 4 weeks ago - Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed - TheFly
- 4 weeks ago - Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - PRNewsWire
- 5 weeks ago - B. Riley cuts Immunic target, sees ‘compelling entry point’ - TheFly
- 5 weeks ago - Immunic appoints Michael Bonney as chair - TheFly